Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE), a biotechnology company specializing in antibody engineering and precision medicine for Inflammatory Bowel Disease (IBD), will participate in the Jefferies Global Healthcare Conference. The event will feature a fireside chat and investor meetings on June 5, 2024, at 9:30 a.m. Eastern time. The webcast will be available on the Spyre website for 90 days post-conference.

Positive

• Spyre Therapeutics' participation in the Jefferies Global Healthcare Conference increases its visibility and potential investor interest.
• The focus on advanced antibody engineering and precision medicine is a strong business direction, catering to the needs of IBD patients.

Negative

• No new clinical data or financial figures were disclosed, leaving investors without updated performance metrics.
• The press release does not mention any immediate revenue-generating activities or partnerships.

WALTHAM, Mass., May 29, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference. Details of the fireside are as follows:

• Wednesday, June 5, 2024, at 9:30 a.m. Eastern time  

To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay for 90 days following the end of the conference.

About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-302157591.html

SOURCE Spyre Therapeutics, Inc.

FAQ

When will Spyre Therapeutics participate in the Jefferies Global Healthcare Conference?

Spyre Therapeutics will participate on June 5, 2024, at 9:30 a.m. Eastern time.

What is the focus of Spyre Therapeutics?

Spyre Therapeutics focuses on antibody engineering, rational therapeutic combinations, and precision medicine for the treatment of Inflammatory Bowel Disease (IBD).

How can investors access the webcast of Spyre Therapeutics' fireside chat?

Investors can access the webcast on the 'Events & Presentations' page within the Investors section of the Spyre website at ir.spyre.com.

How long will the webcast be available for replay?

The webcast will be available for replay for 90 days following the end of the conference.